摘要
目的探讨单磷酸阿糖腺苷联合丙种球蛋白治疗小儿重症手足口病的临床效果。方法选取2013年3月至2015年3月间我院收治的小儿重症手足口病患者140例,随机均分为两组,对照组采取单磷酸阿糖腺苷治疗,观察组采用单磷酸阿糖腺苷联合丙种球蛋白治疗,比较两组患儿的治疗效果。结果观察组的体温恢复时间、神经系统恢复时间均显著短于对照组(P<0.05)。观察组的皮疹治疗总有效率为85.71%,显著高于对照组的65.71%(P<0.05);观察组的临床总有效率为91.43%,显著高于对照组的57.57%(P<0.05)。结论单磷酸阿糖腺苷联合丙种球蛋白治疗小儿重症手口足病的临床疗效显著,值得临床推广使用。
Objective To explore the clinical effect ofvidarabine monophosphate combined with gamma globulin for the treatment of children with severe hand-foot-mouth disease （HFMD）. Methods A total of 140 cases of children with HFMD admitted to our hospital from March 2013 to March 2015 were selected and randomly divided into two groups equally. The observation group was treated with vidarabine monophosphate combined with gamma globulin, while the control group was treated with vidarabine monophosphate only. The clinical curative effects of two groups were observed and compared. Results The time for body temperature recovery and time for neurological recovery of observation group were significantly shorter than those of control group （P〈0.05）. The total effective rate for rash of observation group was 85.71%, significantly higher than 65.71% of control group （P 〈0.05）. The total effective rate of treatment of observation group was 91.43%, significantly higher than 57.57% of control group （P〈0.05）. Conclusions The combined therapy ofvidarabine monophosphate and gamma globulin for the treatment of children with HFMD has significant clinical efficacy, which is worthy of clinical promotion.
出处
《临床医学工程》
2016年第5期645-646,共2页
Clinical Medicine & Engineering
关键词
单磷酸阿糖腺苷
丙种球蛋白
小儿重症口足症
临床疗效
Vidarabine monophosphate
Gamma globulin
Pediatric severe hand-foot-mouth disease
Clinical effect
